Martinsried/Munich, December 08, 2005
MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) today announced an updated guidance for the financial year 2005. Revenue guidance for 2005 was increased from EUR 30 million to EUR 31.5 million and net income guidance was raised from EUR 2.0 million to EUR 3.5 million. Expense guidance for the full year remained unchanged at EUR 28 million. This guidance represents the Company’s year-end financial expectations which incorporate today’s announced extension of the collaboration with Bayer.“Our improved financial expectations for this year continue to underscore the Company's strong underlying performance and success in attracting quality partners such as Bayer,' commented Dave Lemus, Chief Financial Officer at MorphoSys AG.